- Home
- ADN vs SNGX Comparison
ADN vs SNGX Comparison
Compare ADN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- SNGX
- Stock Information
- Founded
- ADN 2006
- SNGX 1987
- Country
- ADN United States
- SNGX United States
- Employees
- ADN N/A
- SNGX N/A
- Industry
- ADN Power Generation
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- SNGX Health Care
- Exchange
- ADN Nasdaq
- SNGX Nasdaq
- Market Cap
- ADN 8.5M
- SNGX 9.6M
- IPO Year
- ADN N/A
- SNGX 1987
- Fundamental
- Price
- ADN $5.00
- SNGX $3.16
- Analyst Decision
- ADN
- SNGX
- Analyst Count
- ADN 0
- SNGX 0
- Target Price
- ADN N/A
- SNGX N/A
- AVG Volume (30 Days)
- ADN 62.8K
- SNGX 46.1K
- Earning Date
- ADN 10-15-2024
- SNGX 11-08-2024
- Dividend Yield
- ADN N/A
- SNGX N/A
- EPS Growth
- ADN N/A
- SNGX N/A
- EPS
- ADN N/A
- SNGX N/A
- Revenue
- ADN $7,026,000.00
- SNGX $364,183.00
- Revenue This Year
- ADN $2,232.99
- SNGX N/A
- Revenue Next Year
- ADN $91.56
- SNGX $76.64
- P/E Ratio
- ADN N/A
- SNGX N/A
- Revenue Growth
- ADN 9.01
- SNGX N/A
- 52 Week Low
- ADN $1.71
- SNGX $1.83
- 52 Week High
- ADN $10.11
- SNGX $19.20
- Technical
- Relative Strength Index (RSI)
- ADN 45.74
- SNGX 41.70
- Support Level
- ADN $5.79
- SNGX $2.93
- Resistance Level
- ADN $6.77
- SNGX $3.35
- Average True Range (ATR)
- ADN 0.64
- SNGX 0.19
- MACD
- ADN -0.17
- SNGX -0.01
- Stochastic Oscillator
- ADN 34.44
- SNGX 37.10
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).